BMY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 24, 2026Sponsor estimate | NCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Alzheimer Disease | BMYLead | Phase 3 | Recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT06146660A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · Obstructive Hypertrophic Cardiomyopathy | BMYLead | No phase registered | Recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07681076Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersKaruna Therapeutics, Inc., a Bristol Myers Squibb company · Healthy Volunteers | BMYLead | Phase 4 | Recruiting | Locked | Locked | Locked |
- Primary completion Nov 24, 2026Sponsor estimatePhase 3NCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Alzheimer DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT06146660A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · Obstructive Hypertrophic CardiomyopathyRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 4NCT07681076Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersKaruna Therapeutics, Inc., a Bristol Myers Squibb company · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT00825929Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.Radboud University Medical Center · HIV Infections
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT03340129Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)Melanoma Institute Australia · Melanoma Stage IvRecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT04204837Nivolumab for Treatment of Squamous Cell Carcinoma of the SkinSalzburger Landeskliniken · Squamous Cell Carcinoma of the SkinRecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT04900818Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsI-Mab Biopharma US Limited · Solid TumorRecruitingNBPLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT04912765Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRCNational Cancer Centre, Singapore · Hepatocellular CarcinomaRecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06151236Neoadjuvant Nivolumab and Relatlimab in Merkel Cell CarcinomaMelanoma Institute Australia · Merkel Cell CarcinomaRecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 5, 2026Sponsor estimatePhase 1NCT07777133A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy...Bristol-Myers Squibb · Healthy Female ParticipantsRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 9, 2026Sponsor estimatePhase 3NCT06126224A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Psychosis Associated With Alzheimer's DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2026Sponsor estimateNo phase registeredNCT07557498Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the USBristol-Myers Squibb · Obstructive Hypertrophic Cardiomyopathy (oHCM)RecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2026Sponsor estimatePhase 1NCT07763418A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal...Bristol-Myers Squibb · Kidney Failure, ChronicRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 1NCT07226817A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult ParticipantsBristol-Myers Squibb · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 19, 2026Sponsor estimatePhase 1NCT07837115A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of...Celgene · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 27, 2026Sponsor estimatePhase 1NCT07655518A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult...Bristol-Myers Squibb · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT03297606Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)Canadian Cancer Trials Group · Lymphoma, Non-Hodgkin
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT05492123Nivolumab-ipilimumab and Chemoradiation for Cervical CancerHospital Israelita Albert Einstein · Uterine Cervical NeoplasmsRecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT06209619CC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaNathan Denlinger · B-Cell Non-Hodgkin Lymphoma-RecurrentRecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06534125Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast CancerEmory University · Anatomic Stage I Breast Cancer AJCC v8RecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06551129Real-world Patient Reported Outcomes Among Patients Treated With CamzyosBristol-Myers Squibb · Obstructive Hypertrophic CardiomyopathyRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT07541833Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)Bristol-Myers Squibb · CardiomyopathyRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 2027Sponsor estimate | NCT03465592Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With SarcomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sarcoma | BMYCollaborator | Phase 1/Phase 2 | Recruiting | Locked | Locked | Locked |
| Jan 2027Sponsor estimate | NCT06026410KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsKura Oncology, Inc. · Solid Tumors With HRAS Alterations | KURALeadBMYCollaborator | Phase 1 | Recruiting | Locked | Locked | Locked |
| Jan 6, 2027Sponsor estimate | NCT06481306A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseBristol-Myers Squibb · Anemia, Sickle Cell | BMYLead | Phase 1/Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 2027Sponsor estimatePhase 1/Phase 2NCT03465592Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With SarcomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · SarcomaRecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT06026410KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsKura Oncology, Inc. · Solid Tumors With HRAS AlterationsRecruitingKURALeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2027Sponsor estimatePhase 1/Phase 2NCT06481306A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseBristol-Myers Squibb · Anemia, Sickle CellRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 2 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.